Executive Summary
Zoetis generated $9.5 billion in revenue in 2025, up 2%, while net income rose 8% to $2.7 billion. Companion animal strength offset livestock declines and divestiture impacts.
What happened
Zoetis reported revenue of $9.5 billion for 2025, up 2% from 2024. Operational revenue growth was 3%, offset by 1% unfavorable foreign exchange. Net income attributable to Zoetis increased 8% to $2.7 billion. The company's top five product lines (Simparica/Simparica Trio, Apoquel/Apoquel Chewable, Cytopoint, Librela, and the ceftiofur line) contributed approximately 42% of total revenue. Revenue growth was driven by price increases of approximately 4% and volume growth from other in-line products of approximately 1%, partially offset by a 3% volume decrease related to the divestiture of the medicated feed additive product portfolio. Companion animal revenue grew 5% to $6.6 billion, driven by increased sales of Simparica Trio, dermatology products, and diagnostics in the U.S., and continued growth in the Simparica franchise, dermatology products, and monoclonal antibody products for osteoarthritis pain (Librela and Solensia) internationally. Livestock revenue declined 5% to $2.8 billion, primarily due to the MFA divestiture. Excluding this impact, livestock revenue increased, driven by higher vaccine demand in cattle and poultry markets. The International segment benefited from operational changes tied to the expected fiscal year alignment, which accelerated approximately 2.5% to 3.5% of sales into Q4 2025, a shift not expected to recur. Cost of sales as a percentage of revenue improved from 29.4% to 28.2%, driven by the favorable impact of the MFA divestiture, price increases, favorable foreign exchange, and lower inventory charges. Operating cash flow was $2.9 billion, down slightly from $3.0 billion in 2024 due to inventory build-up and timing of receipts and payments. The company repurchased 23.9 million shares for $3.2 billion and issued $2 billion in convertible senior notes in December 2025.
Why it matters for investors
The 8% increase in net income despite only 2% revenue growth reflects improving operational efficiency and a higher-margin business mix following the divestiture of lower-margin medicated feed additives. The shift from 29.4% to 28.2% cost of sales as a percentage of revenue demonstrates structural margin expansion. The 5% growth in companion animal products, which now represent 70% of total revenue, underscores the company's strategic pivot toward higher-value veterinary care for pets. However, the livestock business faced headwinds from the divestiture and softer demand, particularly in swine. The one-time acceleration of International sales into Q4 2025 (2.5% to 3.5% of segment revenue) creates a difficult comparison for 2026, as this timing shift will not repeat. The company's ability to generate nearly $3 billion in operating cash flow while repurchasing $3.2 billion in shares and maintaining a $9.2 billion debt load reflects strong free cash flow generation. Concentration risk remains material, with the top five product lines accounting for 42% of revenue. Generic competition continues to pressure legacy products like Draxxin, which declined 66% in the U.S. since generic entry in 2021. The company's effective tax rate remained stable at approximately 20%.
Bullish points
Net income grew 8% to $2.7 billion, outpacing 2% revenue growth, driven by margin expansion and cost discipline following portfolio optimization.
Companion animal revenue increased 5% to $6.6 billion, representing 70% of total revenue, led by strong performance in Simparica Trio, dermatology franchises, and monoclonal antibody pain products.
Operating margin improved to approximately 35.5%, with cost of sales declining from 29.4% to 28.2% of revenue, reflecting favorable business mix and operational efficiency.
Operating cash flow remained strong at $2.9 billion, supporting aggressive capital return with $3.2 billion in share repurchases and continued dividend payments of $0.50 per share quarterly.
The company maintained diversification across 300 product lines in over 100 countries, with the International segment growing 4% operationally despite 1% foreign exchange headwinds.
Bearish points
Livestock revenue declined 5% to $2.8 billion, with the MFA divestiture contributing a 3% volume drag, signaling ongoing weakness in this segment despite excluding the divestiture impact.
The company accelerated 2.5% to 3.5% of International segment sales into Q4 2025 for fiscal year alignment purposes, creating a revenue headwind in 2026 as this timing shift will not recur.
Generic competition continues to erode legacy products, with Draxxin sales down 66% in the U.S. since generic entry began in 2021, and similar pressure on Rimadyl chewable.
The top five product lines contributed 42% of revenue, creating concentration risk if competitive dynamics shift or regulatory actions affect key franchises like Simparica or Apoquel.
Operating cash flow declined slightly from $3.0 billion to $2.9 billion due to inventory build-up and timing of receipts and payments, while the company maintains $9.2 billion in total debt.
Key highlights
Zoetis operates as the world's largest animal health company, managing operations through U.S. and International segments serving both companion animals and livestock. The company directly markets products to veterinarians and livestock producers in approximately 45 countries. Revenue concentration remains elevated, with the top two products (Simparica/Simparica Trio at approximately 16% and Apoquel/Apoquel Chewable at approximately 12%) contributing roughly 28% of total revenue. The U.S. segment revenue remained flat at $5.1 billion, with companion animal growth of $166 million offset by a $143 million decline in livestock due primarily to the MFA divestiture. Excluding this divestiture impact, U.S. livestock revenue increased due to higher vaccine demand in cattle and poultry. The International segment grew 4% to $4.3 billion, with operational growth of 5% offset by 1% unfavorable foreign exchange. International companion animal operational revenue growth was driven by the Simparica franchise, dermatology products, and monoclonal antibodies for osteoarthritis pain (Librela and Solensia). International livestock operational revenue grew due to increased cattle and fish product sales, partially offset by lower poultry sales. Excluding the MFA divestiture, international livestock revenue increased across all species. The company recognized that operational changes for the expected fiscal year alignment led to an acceleration of approximately 2.5% to 3.5% of International segment sales into the reported fourth quarter of 2025. This included shifting the timing of annual price increases in certain international subsidiaries and delaying processing of certain customer orders from December 2025 to calendar year 2026. The effective tax rate was 20.4% in 2025 compared to 20.3% in 2024. Total debt outstanding was approximately $9.2 billion as of December 31, 2025, including the newly issued $2 billion convertible senior notes and $1.85 billion in senior notes issued in August 2025. The company used proceeds to redeem $1.35 billion in maturing senior notes and fund share repurchases. Goodwill totaled $2.8 billion and identifiable intangible assets totaled $1.0 billion, both subject to impairment risk. The company operates 21 manufacturing sites in 10 countries and employs over 90 third-party contract manufacturing organizations.
Management commentary
Management stated that the animal health industry focuses on both companion animals (primarily dogs, cats, and horses) and livestock (primarily cattle, swine, poultry, fish, and sheep). Factors influencing companion animal growth include increasing pet owner commitment to health and well-being, economic development and rising disposable income in emerging markets, longer-living companion animals, increasing medical treatment, and advances in medicines, vaccines, and diagnostics. For livestock, growth drivers include human population growth, rising living standards in emerging markets, increasing demand for animal protein, natural resource constraints, urbanization, and focus on food safety and security. Management noted that the company faces challenges from global economic conditions, inflation, shortages in veterinary healthcare workers, and cost sensitivity among customers, though historical demand for products has been more stable than other production inputs. The company highlighted that its broad and innovative portfolio contributes to the ability to incorporate inflationary challenges into product pricing. Management disclosed that in connection with the expected fiscal year alignment in 2026, operational changes resulted in the acceleration of approximately 2.5% to 3.5% of International segment sales into the reported fourth quarter of 2025, a trend not expected to recur. The company also implemented shifts in early 2026 to the timing of annual price increases in certain international subsidiaries and delayed processing of certain customer orders from December 2025 to calendar year 2026. Management emphasized that the company maintains a diversified portfolio of approximately 300 product lines sold in over 100 countries. Management acknowledged that total revenue attributable to antibacterials for livestock was approximately $713 million for the year ended December 31, 2025, and that restrictions on antibacterial usage and consumer preferences in some markets may negatively impact sales but in other instances may increase sales of antibacterial alternatives. The company stated it is in the process of a multi-year implementation to update its enterprise resource planning system to a new fully cloud-based system.
What to watch next
Investors should monitor:
Impact of the one-time fiscal year alignment benefit of 2.5% to 3.5% on International segment comparisons in 2026, as this sales acceleration will create a revenue headwind.
Trajectory of livestock segment recovery, particularly following the MFA divestiture and amid ongoing demand softness in swine markets.
Continued generic erosion of legacy franchises like Draxxin and Rimadyl, and timing of potential generic entry for key products as patents expire.
Progress on companion animal key franchises, particularly Simparica Trio, Apoquel, Cytopoint, and Librela, which collectively drive significant revenue concentration.
Execution of the multi-year enterprise resource planning system implementation and whether operational disruptions or integration risks materialize as the company transitions systems.
This summary is based solely on excerpts from the company's Form 10-K filing.